MARKET INDEX
KOSPI5,137.89▲ 1.39%
KOSDAQ684.81▲ 5.35%
S&P 5007,323.63▼ 0.23%
NASDAQ24,429.89▲ 0.42%
USD/KRW1,329.83▼ 2.71 (-0.20%)
WTI Crude$82.12▼ 0.23%
BTC/USD$63,822▲ 1.33%
KOSPI5,137.89▲ 1.39%
KOSDAQ684.81▲ 5.35%
S&P 5007,323.63▼ 0.23%
NASDAQ24,429.89▲ 0.42%
USD/KRW1,329.83▼ 2.71 (-0.20%)
WTI Crude$82.12▼ 0.23%
BTC/USD$63,822▲ 1.33%
헤더 좌
헤더 우
BREAKING
MARKET Times 공식 배너

HLB and HLB Life Science Revive Merger Plan to Consolidate Rivoceranib Rights

Integration of domestic development and sales rights alongside overseas profit participation rights to expand synergies in new drug commercialization. Strengthening shareholder communication and driving management effici

HLB and HLB Life Science Revive Merger Plan to Consolidate Rivoceranib Rights
MTIMES Archive / Photo

Integration of domestic development and sales rights alongside overseas profit participation rights to expand synergies in new drug commercialization.

Strengthening shareholder communication and driving management efficiency with a target merger date of June 2027.

HLB and HLB Life Science are reviving their merger plans after a previous attempt failed last year. The strategy aims to integrate business capabilities from drug development to commercialization, enhance management efficiency, and ultimately boost corporate value.

Both companies announced on the 19th that their respective boards of directors have approved a plan for HLB to absorb HLB Life Science.

The merger ratio is set at 0.0857532 shares of HLB for every one share of HLB Life Science. The merger values were calculated at 30,063 KRW for HLB and 2,578 KRW for HLB Life Science. The target date for the completion of the merger is June 30, 2027.

Consolidating Rights for Rivoceranib to Bolster Commercialization

The core of this merger is the consolidation of business rights for the liver cancer drug candidate, Rivoceranib.

HLB will secure the exclusive domestic development and sales rights for Rivoceranib, currently held by HLB Life Science, as well as profit participation rights for the Japanese and European markets. The strategy is to unify scattered rights related to the new drug to improve the efficiency of development and commercialization.

The business environment for new drugs has also shifted. In September, HLB secured U.S. Food and Drug Administration (FDA) approval for its bile duct cancer drug, 'Rivive' (lirafugratinib), through its U.S. subsidiary, Elevar Therapeutics.

Additionally, the combination therapy of Rivoceranib and camrelizumab has entered the FDA's main review process, with a target decision date of April 9, 2027.

Both companies plan to integrate R&D personnel and resources while expanding synergies between medical supplies and existing healthcare businesses. They also intend to reduce costs and improve profitability by streamlining management support functions and internal transaction structures.

Overcoming Past Hurdles: Shareholder Approval Remains Key

The companies previously attempted a merger last year but withdrew after the stock purchase claims from HLB Life Science shareholders exceeded the 40 billion KRW threshold stipulated in the contract.

At that time, the merger ratio was 0.1167458 shares of HLB per share of HLB Life Science. This has been adjusted to 0.0857532 shares. As the ratio reflects current stock prices, shareholder assessment of the new terms will be critical.

Both companies have established special committees composed of three independent directors each and have engaged external experts to review the fairness of the merger terms. They also plan to operate shareholder meetings and dedicated Q&A channels on their websites.

A company official stated, "This merger is a strategic decision to build a management system optimized for new drug commercialization by integrating the R&D capabilities and business foundations of both companies."

Ultimately, the success of the merger depends on persuading shareholders and the scale of stock purchase claims. In the mid-to-long term, FDA approval for Rivoceranib and tangible profitability improvements following the integration will be the key variables for the revaluation of corporate value.

MARKET Times

MTIMES Global Editorial Statement

This analysis is provided for international business intelligence and informational purposes only. It does not constitute investment advice or a solicitation to buy or sell securities. For inquiries regarding licensing or syndication, please contact [email protected].

← More in CorporateBack to Top ↑

Related Market & Corporate Intelligence

The Robotaxi Arms Race: Can Waymo Maintain Its Lead Amid Safety Hurdles?The Robotaxi Arms Race: Can Waymo Maintain Its Lead Amid Safety Hurdles?South Korea Surpasses $1 Trillion in Annual Exports for First Time, Joining Global EliteSouth Korea Surpasses $1 Trillion in Annual Exports for First Time, Joining Global EliteFed Minutes Reveal Consensus for Further Hikes; Wall Street Divided on January OutlookFed Minutes Reveal Consensus for Further Hikes; Wall Street Divided on January OutlookSigns of Thaw in China Ties: Retail, Travel, and Beauty Sectors Eye New Opportunities Following FTA BreakthroughSigns of Thaw in China Ties: Retail, Travel, and Beauty Sectors Eye New Opportunities Following FTA Breakthrough
HomeTOP10AlmatenPicksCorpAlgiten